Diabetes Type 2 Clinical Trial
Official title:
Enhancing Digitally Delivered Diabetes Education With Real-Time CGM: A Comparative Study in People With Type 2 Diabetes
The current research study will add continuous glucose monitoring devices to the evidence-based text messaging diabetes education program for patients with type 2 diabetes for 6 months. Results on the effectiveness of this intervention will be compared for non-insulin using patients.
The current research study seeks to investigate the impact of incorporating Continuous Glucose Monitoring (CGM) into the evidence-based text messaging diabetes education program, Dulce Digital, focusing on individuals with Type 2 Diabetes (T2D) who are not on insulin therapy. This innovative approach stems from the rationale that real-time continuous glucose monitoring (CGM) can offer valuable insights into glycemic control, thereby enhancing diabetes self-management. In standard care, individuals with T2D, particularly those not on insulin, may not routinely have access to CGM devices. The CGM device, an integral part of recommended diabetes therapy, is FDA approved for use in all people with diabetes. However, reimbursement for CGM devices varies by health plans, and currently, Centers for Medicare & Medicaid Services (CMS) does not reimburse for their use in non-insulin-using diabetes, except in cases of repeated severe hypoglycemia. Despite this, the investigators hypothesize that there are both clinical and financial benefits to providing a CGM device during diabetes self-management education for individuals with non-insulin-using T2D. This study aims to determine if adding a CGM device for this patient category yields significant benefits, contributing to the understanding of the potential advantages and informing future diabetes care practices. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Active, not recruiting |
NCT04954313 -
Baseline Oral Health Study: UnCoVer the Connections to General Health
|
Phase 4 | |
| Not yet recruiting |
NCT06437782 -
Exploration of Health Literacy in Diabetes in Reunion Island and France
|
||
| Completed |
NCT01354925 -
Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan
|
Phase 4 | |
| Completed |
NCT01206725 -
Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction
|
N/A | |
| Completed |
NCT00997282 -
A Study of OPC-262 in Patients With Type 2 Diabetes
|
Phase 2/Phase 3 | |
| Completed |
NCT00637546 -
Gait and Balance of Diabetes Type 2 Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT00464880 -
Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02057497 -
An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms
|
N/A | |
| Active, not recruiting |
NCT05014204 -
Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes
|
N/A | |
| Recruiting |
NCT03662217 -
Personalized Nutrition for Diabetes Type 2
|
N/A | |
| Completed |
NCT04276051 -
Cryovagotomy Diabetes Trial
|
N/A | |
| Completed |
NCT02569684 -
Effects of Prebiotics on GLP-1 in Type 2 Diabetes
|
N/A | |
| Active, not recruiting |
NCT01933529 -
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
|
Phase 2 | |
| Terminated |
NCT01722474 -
Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.
|
N/A | |
| Completed |
NCT00977262 -
Postprandial Inflammation and Fatty Acids
|
N/A | |
| Completed |
NCT00518427 -
Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine
|
Phase 4 | |
| Recruiting |
NCT05378620 -
Project Dulce for Filipino-Americans With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT03834207 -
A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy
|
N/A | |
| Active, not recruiting |
NCT05228067 -
Enhancing Brain Health by tDCS in Persons With Overweight and Obesity
|
N/A |